Complement Inhibition in Rare Kidney Disease: Response Heterogeneity and Biomarker-Guided Withdrawal
DOI:
https://doi.org/10.5281/zenodo.22649336Keywords:
Complement Inhibition in Rare Kidney Disease; Translational medicine, Evidence synthesis; Clinical implementation; Health services researchAbstract
Complement Inhibition in Rare Kidney Disease is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for complement inhibition in rare
kidney disease, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice
has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its
adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1007/s10916-024-02104-9
Brankovic K, Kowalczyk B, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.3389/fdgth.2026.1896184
Castellani R, Ristic C, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3390/diagnostics15162117
Dumitrescu A, Andric D, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.4103/jrpp.jrpp_20_65
Eriksdottir B, Brankovic E, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3389/fdgth.2026.1763884
Farkas I, Ionescu F, et al. "Complement Inhibition in Rare Kidney Disease: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.2196/48297
Grabowski P, Petrescu G, et al. "Complement Inhibition in Rare Kidney Disease: a retrospective analysis". BMJ Open 20(2014):7 146-158. DOI: 10.1007/s00330-025-12031-z
Hendriksen W, Wojcik H, et al. "Complement Inhibition in Rare Kidney Disease: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.3389/fdgth.2026.1699005
Ionescu F, Foscarini I, et al. "Complement Inhibition in Rare Kidney Disease: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.3389/fdgth.2026.1834800
Jankowiak G, Grabowski J, et al. "Complement Inhibition in Rare Kidney Disease: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.2196/69678
Kowalczyk N, Novotna K, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.7759/cureus.46454
Lindqvist U, Urbanek L, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.1016/j.ssci.2025.107028
Marchetti D, Doncheva M, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.2196/48633
Novotna E, Eriksdottir N, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1371/journal.pone.0305949
Ostrowski L, Lindqvist O, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1371/journal.pdig.0000514
Petrescu S, Szabo P, et al. "Complement Inhibition in Rare Kidney Disease: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.17219/acem/208596
Quintero B, Balogh Q, et al. "Complement Inhibition in Rare Kidney Disease: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.7759/cureus.104086
Ristic C, Castellani R, et al. "Complement Inhibition in Rare Kidney Disease: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1038/s41746-023-00852-5
Szabo J, Jankowiak S, et al. "Complement Inhibition in Rare Kidney Disease: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1016/j.mayocpiqo.2022.09.004
Tarasov Q, Quintero T, et al. "Complement Inhibition in Rare Kidney Disease: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1177/08404704241291226
Urbanek Z, Zielinski U, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1093/medlaw/fwad013
Vasquez A, Alvez V, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.2196/89834
Wojcik H, Hendriksen W, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1007/s10916-024-02104-9
Zielinski O, Ostrowski Z, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.3389/fdgth.2026.1896184
Andric V, Vasquez A, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3390/diagnostics15162117
Balogh E, Emmerich B, et al. "Complement Inhibition in Rare Kidney Disease: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.4103/jrpp.jrpp_20_65
Chiriac F, Farkas C, et al. "Complement Inhibition in Rare Kidney Disease: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3389/fdgth.2026.1763884
Doncheva M, Marchetti D, et al. "Complement Inhibition in Rare Kidney Disease: a validation study". Trials 22(2017): 377-383. DOI: 10.2196/48297
Emmerich T, Tarasov E, et al. "Complement Inhibition in Rare Kidney Disease: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1007/s00330-025-12031-z
Foscarini C, Chiriac F, et al. "Complement Inhibition in Rare Kidney Disease: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.3389/fdgth.2026.1699005
Alvez D, Dumitrescu A, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.3389/fdgth.2026.1834800
Brankovic K, Kowalczyk B, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.2196/69678
Castellani R, Ristic C, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.7759/cureus.46454
Dumitrescu A, Andric D, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.1016/j.ssci.2025.107028
Eriksdottir B, Brankovic E, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.2196/48633
Farkas I, Ionescu F, et al. "Complement Inhibition in Rare Kidney Disease: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1371/journal.pone.0305949
Grabowski P, Petrescu G, et al. "Complement Inhibition in Rare Kidney Disease: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1371/journal.pdig.0000514
Hendriksen W, Wojcik H, et al. "Complement Inhibition in Rare Kidney Disease: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.17219/acem/208596
Ionescu F, Foscarini I, et al. "Complement Inhibition in Rare Kidney Disease: a scoping review". JAMA 44(2020): 498-506. DOI: 10.7759/cureus.104086
Jankowiak G, Grabowski J, et al. "Complement Inhibition in Rare Kidney Disease: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1038/s41746-023-00852-5
Kowalczyk N, Novotna K, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1016/j.mayocpiqo.2022.09.004
Lindqvist U, Urbanek L, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1177/08404704241291226
Marchetti D, Doncheva M, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1093/medlaw/fwad013
Novotna E, Eriksdottir N, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.2196/89834
Ostrowski L, Lindqvist O, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1007/s10916-024-02104-9
Petrescu S, Szabo P, et al. "Complement Inhibition in Rare Kidney Disease: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.3389/fdgth.2026.1896184
Quintero B, Balogh Q, et al. "Complement Inhibition in Rare Kidney Disease: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3390/diagnostics15162117
Ristic C, Castellani R, et al. "Complement Inhibition in Rare Kidney Disease: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.4103/jrpp.jrpp_20_65
Szabo J, Jankowiak S, et al. "Complement Inhibition in Rare Kidney Disease: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3389/fdgth.2026.1763884
Tarasov Q, Quintero T, et al. "Complement Inhibition in Rare Kidney Disease: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.2196/48297
Urbanek Z, Zielinski U, et al. "Complement Inhibition in Rare Kidney Disease: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1007/s00330-025-12031-z
Vasquez A, Alvez V, et al. "Complement Inhibition in Rare Kidney Disease: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.3389/fdgth.2026.1699005
Wojcik H, Hendriksen W, et al. "Complement Inhibition in Rare Kidney Disease: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.3389/fdgth.2026.1834800
Zielinski O, Ostrowski Z, et al. "Complement Inhibition in Rare Kidney Disease: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.2196/69678
Andric V, Vasquez A, et al. "Complement Inhibition in Rare Kidney Disease: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.7759/cureus.46454
